Cme Group Stock Current Valuation
| MX4A Stock | EUR 228.75 0.10 0.04% |
Valuation analysis of CME Group helps investors to measure CME's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Undervalued
Today
Please note that CME's price fluctuation is very steady at this time. Calculation of the real value of CME Group is based on 3 months time horizon. Increasing CME's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the CME stock is determined by what a typical buyer is willing to pay for full or partial control of CME Group. Since CME is currently traded on the exchange, buyers and sellers on that exchange determine the market value of CME Stock. However, CME's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 228.75 | Real 261.05 | Hype 228.75 | Naive 226.87 |
The real value of CME Stock, also known as its intrinsic value, is the underlying worth of CME Group Company, which is reflected in its stock price. It is based on CME's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of CME's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of CME Group helps investors to forecast how CME stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of CME more accurately as focusing exclusively on CME's fundamentals will not take into account other important factors: CME Group Company Current Valuation Analysis
CME's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current CME Current Valuation | 60.85 B |
Most of CME's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, CME Group is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, CME Group has a Current Valuation of 60.85 B. This is 85.42% higher than that of the Financial Services sector and 116.06% higher than that of the Financial Exchanges industry. The current valuation for all Germany stocks is significantly lower than that of the firm.
CME Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CME's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of CME could also be used in its relative valuation, which is a method of valuing CME by comparing valuation metrics of similar companies.CME is currently under evaluation in current valuation category among its peers.
CME Fundamentals
| Return On Equity | 0.0992 | |||
| Return On Asset | 0.0101 | |||
| Profit Margin | 0.54 % | |||
| Operating Margin | 0.60 % | |||
| Current Valuation | 60.85 B | |||
| Shares Outstanding | 359.72 M | |||
| Shares Owned By Insiders | 0.45 % | |||
| Shares Owned By Institutions | 88.31 % | |||
| Price To Earning | 35.53 X | |||
| Price To Book | 2.16 X | |||
| Price To Sales | 12.30 X | |||
| Revenue | 5.02 B | |||
| Gross Profit | 5.01 B | |||
| EBITDA | 4.02 B | |||
| Net Income | 2.69 B | |||
| Cash And Equivalents | 1.02 B | |||
| Cash Per Share | 2.86 X | |||
| Total Debt | 3.42 B | |||
| Debt To Equity | 15.30 % | |||
| Current Ratio | 1.05 X | |||
| Book Value Per Share | 74.89 X | |||
| Cash Flow From Operations | 3.06 B | |||
| Earnings Per Share | 6.98 X | |||
| Price To Earnings To Growth | 4.38 X | |||
| Target Price | 221.47 | |||
| Number Of Employees | 3.46 K | |||
| Beta | 0.41 | |||
| Market Capitalization | 62.87 B | |||
| Total Asset | 174.18 B | |||
| Z Score | 10.8 | |||
| Annual Yield | 0.02 % | |||
| Five Year Return | 1.84 % | |||
| Net Asset | 174.18 B | |||
| Last Dividend Paid | 4.0 |
About CME Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CME Group's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CME using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CME Group based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in CME Stock
When determining whether CME Group is a strong investment it is important to analyze CME's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact CME's future performance. For an informed investment choice regarding CME Stock, refer to the following important reports:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in CME Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.